Fosamax for Paget's Disease: Off-Label Evidence Summary

Clarifying Regulatory Status: Alendronate Is FDA-Approved for Paget's Disease

Contrary to a common misconception, alendronate is not off-label for Paget's disease. The FDA approved Fosamax (alendronate sodium) for Paget's disease of bone in 1995, the same year it received approval for osteoporosis treatment [1]. The approved dose is 40 mg once daily for six months, distinct from the 10 mg daily or 70 mg weekly doses used for osteoporosis.

The confusion likely stems from how infrequently clinicians prescribe alendronate 40 mg specifically for Paget's disease in current practice. Many providers now favor a single intravenous infusion of zoledronic acid, which offers higher remission rates and eliminates concerns about oral adherence over six months [2]. Still, the FDA labeling for alendronate explicitly lists Paget's disease as an approved indication. The Fosamax prescribing information states that treatment is indicated for patients with Paget's disease of bone who have alkaline phosphatase at least two times the upper limit of normal, or who are symptomatic, or who are at risk for future complications [1].

This distinction matters. Insurance coverage, formulary placement, and prior authorization requirements all differ for FDA-approved indications versus true off-label use. Patients prescribed alendronate 40 mg for Paget's disease should not encounter the coverage barriers that genuinely off-label prescriptions sometimes face.

Clinical Trial Evidence for Alendronate in Paget's Disease

Alendronate 40 mg daily normalizes serum alkaline phosphatase in roughly half to two-thirds of Paget's patients over a six-month course. The data supporting this come from several controlled trials conducted in the 1990s that formed the basis of its FDA approval.

In a key randomized, double-blind study by Reid et al. (1996), 55 patients with Paget's disease received alendronate 40 mg/day for six months. SAP normalized in 48% of alendronate-treated patients compared to none in the placebo group. Mean SAP decreased by 73% from baseline [3]. A separate multicenter trial published in the American Journal of Medicine evaluated 89 patients and found SAP normalization rates of 63% with alendronate 40 mg daily over six months [4].

Longer-term follow-up data showed durability. Patients who achieved biochemical remission maintained suppressed SAP levels for a median of 18 to 24 months after stopping alendronate, though individual responses varied considerably [3]. Some patients required retreatment within 12 months, while others remained in remission for three years or longer. The retreatment threshold recommended by most guidelines is an SAP level that rises above the midpoint of the normal reference range or the return of bone pain at a known Paget's site [5].

A comparative trial by Reid et al. (2005) directly compared alendronate 40 mg/day against etidronate 400 mg/day. SAP normalization occurred in 61.4% of the alendronate group versus only 16.7% in the etidronate group (P<0.001), establishing alendronate as clearly superior to the older bisphosphonate [6].

How Alendronate Compares to Zoledronic Acid for Paget's Disease

Zoledronic acid 5 mg as a single intravenous infusion outperforms alendronate 40 mg daily in head-to-head data. The HORIZON-PDB trial (N=357) published in the New England Journal of Medicine in 2005 randomly assigned Paget's patients to either a single 5 mg zoledronic acid infusion or alendronate 40 mg/day for 60 days. At six months, 96% of zoledronic acid patients achieved a therapeutic response versus 74% in the alendronate group (P<0.001) [2].

SAP normalization rates told an even more striking story. Complete normalization occurred in 89% of zoledronic acid patients compared with 63% of alendronate patients [2]. The response was also more durable: at 24-month follow-up, 98% of zoledronic acid responders maintained their therapeutic response versus 57% of alendronate responders [7].

These results explain why the Endocrine Society's 2014 clinical practice guideline recommends zoledronic acid as the preferred bisphosphonate for Paget's disease, with oral bisphosphonates including alendronate as alternatives when intravenous therapy is contraindicated or declined by the patient [5]. Dr. Ethel Siris, a leading Paget's disease researcher at Columbia University, has noted: "Zoledronic acid has become the treatment of choice for most patients with active Paget's disease because a single infusion produces higher and more sustained remission rates than any oral bisphosphonate regimen" [5].

Despite the superiority of zoledronic acid, alendronate retains a clear role. Patients who cannot receive intravenous bisphosphonates due to renal impairment (estimated GFR <35 mL/min), lack of infusion access, or personal preference benefit from having a well-studied oral option. The cost advantage of generic alendronate also matters in practice.

Dosing, Administration, and Practical Guidance

The Paget's disease dose of alendronate is 40 mg orally once daily for six months. This is four times the daily osteoporosis dose. Patients must follow the same strict administration protocol used for osteoporosis dosing to protect the esophagus.

Take the tablet first thing in the morning with 6 to 8 ounces of plain water. Not coffee, not juice. Remain upright (sitting or standing) for at least 30 minutes afterward, and do not eat, drink other beverages, or take other oral medications during that window [1]. These requirements exist because alendronate can cause severe esophageal irritation, and recumbent positioning or coadministration with other substances increases that risk.

Calcium and vitamin D supplementation is recommended during treatment. The Endocrine Society recommends ensuring 25-hydroxyvitamin D levels are above 20 ng/mL before starting bisphosphonate therapy for Paget's disease, with 1,000 to 1 to 500 mg of daily calcium and 800 to 1 to 000 IU of daily vitamin D as standard supportive measures [5]. Inadequate calcium intake during aggressive bisphosphonate treatment of Paget's disease can trigger symptomatic hypocalcemia because the suppression of accelerated bone resorption reduces calcium flux from bone into blood.

The six-month treatment duration is not arbitrary. Biochemical response to alendronate is progressive over the course of treatment, with most of the SAP reduction occurring in the first three months and additional normalization continuing through month six [3]. Shorter courses produce less complete responses.

Monitoring Response and Deciding on Retreatment

Serum alkaline phosphatase is the primary biochemical marker for monitoring Paget's disease activity and treatment response. Measure SAP at baseline, at three months, and at six months (end of treatment), then every six to twelve months thereafter [5].

A therapeutic response is defined as either normalization of SAP or a reduction of at least 75% from the pretreatment elevated level [2]. Bone-specific alkaline phosphatase (BSAP) offers greater specificity than total SAP in patients with concurrent liver disease, though total SAP remains adequate for most clinical scenarios. Complete normalization of SAP correlates with histomorphometric evidence of suppressed pagetic bone turnover and is the preferred endpoint [8].

The Endocrine Society guideline states: "Retreatment should be considered when serum total alkaline phosphatase, measured using the same laboratory and assay, increases above the normal range, or when symptoms attributable to Paget's disease recur" [5]. In practice, many clinicians use a lower threshold for retreatment, acting when SAP rises above the midpoint of the normal range rather than waiting for it to exceed the upper limit [5].

Between 25% and 50% of alendronate-treated patients will need retreatment within two to five years [7]. For retreatment, clinicians can either repeat a course of alendronate 40 mg daily for six months or switch to zoledronic acid 5 mg IV for a potentially more durable response. The choice often depends on the patient's prior tolerance and response durability.

Side Effects and Safety Considerations

Alendronate 40 mg daily for Paget's disease carries the same safety profile as lower doses used for osteoporosis, though the higher dose may increase gastrointestinal side effect frequency. Upper GI complaints are the most common reason for discontinuation.

In the key trials, the most frequently reported adverse events included abdominal pain (6.6%), nausea (3.6%), dyspepsia (3.6%), constipation (3.1%), diarrhea (3.1%), and musculoskeletal pain (2.6%) [4]. Esophageal erosions and ulceration are the most concerning potential complications, though they are uncommon when administration instructions are followed correctly [1].

Rare but serious adverse events associated with bisphosphonate class effects include osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFF). The risk of ONJ is very low in the Paget's disease population receiving a single six-month course of oral alendronate. A 2015 systematic review found that ONJ risk with oral bisphosphonates was approximately 0.001% to 0.01%, with nearly all cases occurring in patients on long-term continuous therapy rather than a single defined course [9]. Similarly, AFF risk correlates with cumulative bisphosphonate exposure exceeding three to five years, which is uncommon in the typical Paget's treatment scenario [10].

Acute-phase reactions (fever, myalgia, headache occurring 24 to 72 hours after the first dose) are far more common with intravenous zoledronic acid (reported in up to 42% of patients in the HORIZON-PDB trial) than with oral alendronate [2]. This difference is sometimes a deciding factor for patients choosing between the two agents.

When Alendronate Is the Right Choice Over Other Options

Several clinical situations favor alendronate over zoledronic acid or other bisphosphonates. Patient preference is one. Some patients prefer taking a daily pill at home to receiving an intravenous infusion in a clinic or infusion center, even when the infusion is a single event.

Renal impairment is another. Zoledronic acid is contraindicated in patients with creatinine clearance <35 mL/min due to risk of renal toxicity [2]. Alendronate can be used with caution in mild to moderate renal impairment (GFR 35 to 60 mL/min), though it is not recommended when GFR falls below 35 mL/min either [1]. For patients with GFR between 35 and 60 mL/min who cannot receive zoledronic acid, alendronate remains a viable option.

Cost considerations also play a role. Generic alendronate 40 mg is available for as little as $10 to $30 for a one-month supply at many pharmacies. Zoledronic acid, while highly effective, involves additional costs for the infusion itself, facility fees, and nursing time. In health systems where infusion center access is limited, oral therapy may be the only practical option.

The AACE/ACE 2019 guidelines on Paget's disease management acknowledge both zoledronic acid and oral bisphosphonates as appropriate choices, with the recommendation that treatment selection should account for disease severity, patient comorbidities, access to infusion services, and patient preference [11]. Mild to moderate Paget's disease with modest SAP elevation (two to three times normal) responds well to alendronate in many cases, reserving zoledronic acid for more severe disease or retreatment failures.

Paget's Disease: Who Needs Treatment and Who Can Be Observed

Not every patient with Paget's disease requires pharmacologic intervention. Treatment is indicated for patients with symptoms attributable to the disease (bone pain, deformity, neurologic complications), those with biochemically active disease (elevated SAP) at sites where complications could develop (skull base, spine, weight-bearing long bones, periarticular locations), and those preparing for elective surgery at a pagetic site to reduce operative bleeding [5].

Asymptomatic patients with isolated SAP elevation and disease limited to non-critical skeletal sites present a more nuanced situation. The Endocrine Society guideline takes an individualized approach, suggesting that treatment may be reasonable even in asymptomatic patients if the goal is to prevent disease progression, though acknowledging that no randomized trial has demonstrated that early treatment prevents long-term complications like deformity or fracture [5].

SAP levels above two times the upper limit of normal generally warrant treatment regardless of symptoms. A patient with a SAP of 450 U/L (normal <120 U/L) affecting the femur has a clear indication for bisphosphonate therapy, whether or not they currently report pain. The target is biochemical remission: SAP within the normal range.